South Korea · Delayed Price · Currency is KRW EuBiologics Statistics
Total Valuation
EuBiologics has a market cap or net worth of KRW 309.09 billion.
| Market Cap | 309.09B |
| Enterprise Value | n/a |
Important Dates
The next estimated earnings date is Wednesday, October 28, 2026.
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
EuBiologics has 36.75 million shares outstanding.
| Current Share Class | 36.75M |
| Shares Outstanding | 36.75M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 4.41% |
| Float | 29.06M |
Valuation Ratios
The trailing PE ratio is 12.43.
| PE Ratio | 12.43 |
| Forward PE | n/a |
| PS Ratio | 3.22 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.84 |
| P/OCF Ratio | 11.68 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 5.28% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.08B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.63% in the last 52 weeks. The beta is 0.19, so EuBiologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | -39.63% |
| 50-Day Moving Average | 8,458.80 |
| 200-Day Moving Average | 11,206.80 |
| Relative Strength Index (RSI) | 44.77 |
| Average Volume (20 Days) | 121,834 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EuBiologics had revenue of KRW 96.04 billion and earned 24.87 billion in profits.
| Revenue | 96.04B |
| Gross Profit | 96.04B |
| Operating Income | 34.32B |
| Pretax Income | 23.78B |
| Net Income | 24.87B |
| EBITDA | n/a |
| EBIT | 34.32B |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
| Cash & Cash Equivalents | n/a |
| Total Debt | n/a |
| Net Cash | n/a |
| Net Cash Per Share | n/a |
| Equity (Book Value) | n/a |
| Book Value Per Share | n/a |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 26.45 billion and capital expenditures -6.94 billion, giving a free cash flow of 19.52 billion.
| Operating Cash Flow | 26.45B |
| Capital Expenditures | -6.94B |
| Depreciation & Amortization | 9.17B |
| Net Borrowing | -1.27B |
| Free Cash Flow | 19.52B |
| FCF Per Share | 531.00 |
Margins
Gross margin is 100.00%, with operating and profit margins of 35.74% and 25.89%.
| Gross Margin | 100.00% |
| Operating Margin | 35.74% |
| Pretax Margin | 24.77% |
| Profit Margin | 25.89% |
| EBITDA Margin | n/a |
| EBIT Margin | 35.74% |
| FCF Margin | 28.13% |
Dividends & Yields
EuBiologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 8.04% |
| FCF Yield | 6.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |